Fosun Pharma Achieves Impressive Growth with Revenue of 41.4 Billion Yuan in 2023

Fosun Pharma, a leading pharmaceutical company, has reported remarkable financial results for the year 2023. With a strong focus on innovation and global expansion, Fosun Pharma has successfully solidified its position in the healthcare industry. This article highlights the company's commitment to driving innovation, its revenue growth, and the success of its groundbreaking products.

Fosun Pharma's Revenue Growth and Innovation Strategy:

In 2023, Fosun Pharma achieved a significant milestone by generating a revenue of 41.4 billion yuan, representing a year-on-year growth of approximately 12.43%. The company's dedication to innovation and its global operational capabilities have played a crucial role in this remarkable achievement. Over the past 30 years, Fosun Pharma has been at the forefront of China's healthcare industry, focusing on technological advancements and patient-centric approaches. By addressing unmet clinical needs, the company has developed a diversified and multi-tiered open innovation model, encompassing independent research and development, collaborative partnerships, licensing agreements, and deep incubation. Fosun Pharma's primary therapeutic areas include oncology (solid tumors and hematological malignancies), immunology, central nervous system disorders, and chronic diseases (such as liver disease, metabolic disorders, and kidney disease).

Impressive Growth of Innovative Products:

During the reporting period, Fosun Pharma's drive for innovation resulted in substantial growth of its key innovative products. Notably, the company obtained regulatory approvals for eight indications across six innovative drugs, including Hansuo (Sulurituzumab Injection), Hanquyou (Sintilimab Injection), and Sukexin (Afatinib Maleate Tablets). Hansuo, an innovative biological drug developed by Fosun Pharma, received regulatory approval for the treatment of extensive-stage small-cell lung cancer (ES-SCLC) and esophageal squamous cell carcinoma (ESCC) in China. It became the world's first PD-1 monoclonal antibody approved for first-line treatment of ES-SCLC. To date, Hansuo has been approved for four indications in China and has benefited over 60,000 Chinese patients. Additionally, Fosun Pharma's joint venture company, Fosun Kite, obtained regulatory approval for the second-line indication of Yikaida (Axicabtagene Ciloleucel Injection), a CAR-T cell therapy product. This approval expanded the treatment options for frontline immunotherapy-resistant or relapsed patients. Yikaida has already benefited over 600 lymphoma patients and has been included in more than 100 provincial and commercial insurance programs, with treatment centers spanning across 25 provinces and over 160 facilities.

Optimized Research and Development (R&D) and Pipeline Advancements:

Fosun Pharma continues to enhance its R&D system, strategically focusing on small molecules, antibodies/ADCs, RNA, and cell therapies. By establishing an open and globalized innovation ecosystem, the company aims to explore cutting-edge technologies such as tumor vaccines and AI drug development. Fosun Pharma's commitment to R&D is evident through its investment of 5.937 billion yuan in 2023, with R&D expenses amounting to 4.346 billion yuan. The pharmaceutical business accounted for 5.172 billion yuan of the R&D investment, primarily dedicated to over 70 innovative drug and biosimilar projects (based on indications). During the reporting period, Fosun Pharma successfully progressed five products with seven indications through independent R&D, collaborative development, and licensing agreements, reaching the pre-approval stage.

Fosun Pharma's financial performance in 2023 reflects its unwavering commitment to innovation and global expansion. With a focus on addressing unmet clinical needs, the company has achieved remarkable growth in revenue and the successful development of innovative products. By continuously optimizing its research and development capabilities, Fosun Pharma is well-positioned to drive the development and commercialization of more first-in-class and best-in-class products. As a leading player in the pharmaceutical industry, Fosun Pharma continues to contribute to the advancement of healthcare and the improvement of patients' lives.